Interview: Fabrizio Greco – General Manager, AbbVie Italy
Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the…
Abbvie is a global innovator focusing on unmet needs in the oncology, immunology, kidney disease, liver disease, neuroscience and women’s health therapeutic areas. The company’s Global CEO is Richard A Gonzales. In Italy Abbvie has a production facility at Campoverde in Aprillia which is producing part of the company’s new HCV treatment. AbbVie has been growing very strongly in Italy, with a turnover of 412 million in 2015. Globally turnover is 20 billion.
Contact
S.R. 148 Pontina Km 52 snc
04011 Campoverde di Aprilia (LT)
Telephone: +39 06 928921
Web: abbvie.it
Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the…
Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in…
The latest news from the Italian healthcare and life sciences industries, including the final piece in Angelini’s updated leadership team; the country’s digital health investment timetable; and the details of…
Formerly known as Assogenerici, Egualia is an Italian industry association representing generics and biosimilar companies. Michele Uda, its director-general, speaks about the industry’s impressive response to the COVID-19 pandemic and…
With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why…
Speaking recently to PharmaBoardoom, Assobiotec’s Leonardo Vingiani introduced the key dynamics shaping the Italian biotech industry today and the issues it still has to overcome to become truly globally competitive.…
Assobiotec’s Leonardo Vingiani introduces the key trends shaping the Italian biotech ecosystem today, the steps that the country’s government have taken to foster life sciences innovation, and the areas in…
Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches…
In recent months, a profound transformation has been occurring right at the core of the Italian pharmaceutical industry as the most significant reforms to market access within two decades start…
The latest Italy Pharma News, including the government’s decision to make COVID-19 vaccines mandatory for all healthcare workers, the manufacturing of Sputnik V, and recent updates from the country’s top…
The latest from Italian pharma, including the foreign minister’s plea for delivering on COVID-19 vaccine contracts, glass vial manufacturer Stevenato’s USD five billion valuation, AIFA’s approval of Novartis’s Zolgensma, and…
A roundup of some of the most important recent stories from Italian pharma, including an in-depth interview with Menarini CEO Elcin Barker Ergun, a public health management crisis in the…
In July 2020, Italy became the first country in the world to mandate pharma companies to disclose data surrounding public subsidies received for the development of new drugs. The decree…
See our Cookie Privacy Policy Here
